Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | NSD2 | O96028 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10383781 | 0.92 | POLB (0.51) | POLBALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5186401 | 0.88 | POLB (0.47) | POLBALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6825630 | 0.88 | POLB (0.47) | POLBALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL231042 | 0.87 | SIRT1 (0.71) | POLBALDH1A1SMN1; SMN2RAB9ASIRT1 | |
| SCHEMBL8531499 | 0.86 | SIRT1 (0.56) | POLBALDH1A1SMN1; SMN2RAB9ASIRT1 | |
| SCHEMBL20591207 | 0.86 | SIRT1 (0.51) | POLBALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2233495 | 0.85 | AKR1C3 (0.56) | POLBALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4543724 | 0.85 | SMN1; SMN2 (0.52) | POLBALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6935437 | 0.84 | SIRT1 (0.58) | POLBALDH1A1SMN1; SMN2RAB9AGAA | |
| SCHEMBL2024004 | 0.84 | ALDH1A1 (0.59) | POLBALDH1A1NPC1RAB9AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943606-B2 | Compositions and methods to control abnormal cell growth | CANCURE LABORATORIES, LLC (US) | 2011-05-17 | — | — | US | claimed |
| US-20100048668-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | CANCURE LABORATORIES, LLC (US) | 2010-02-25 | — | — | US | claimed |
| WO-2024035268-A2 | TAU PATHWAY MODULATORS | QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT (QA) | 2024-02-15 | — | — | WO | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| US-7943606-B2 | Compositions and methods to control abnormal cell growth | CANCURE LABORATORIES, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100048668-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | CANCURE LABORATORIES, LLC (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100022617-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | CANCURE LABORATORIES, LLC (US) | 2010-01-28 | — | — | US | disclosed |
| US-7589083-B2 | [3-(3,4-Dimethyl-9-oxo-9H- thioxanthen-2-yloxy)-2- hydroxypropyl]trimethyl- ammonium chloride; antitumor; simultaneously enhancing the efficacy and decreasing the toxicity of chemotherapy by single agents | CANCURE LABORATORIES, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2008061029-A1 | ARYL SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20070060634-A1 | COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH | ZOLTAN LABORATORIES LLC (US) | 2007-03-15 | — | — | US | disclosed |
| EP-0207350-B1 | PROCESS FOR PREPARING DIARYL SULPHIDES | CASSELLA Aktiengesellschaft (DE) | 1989-01-18 | — | — | EP | disclosed |
| US-4686303-A | Process for the preparation of diaryl sulphides | CASSELLA AKTIENGESELLSCHAFT (DE) | 1987-08-11 | — | — | US | disclosed |
| EP-0207350-A1 | Process for preparing diaryl sulphides | CASSELLA Aktiengesellschaft (DE) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060634-A1 | COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH | ALPP, DNTT, ALPG | POLB 956/4885ALDH1A1 2158/4885SMN1; SMN2 4414/4885 |
| US-20100048668-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | ALPP, ALPG, MKI67 | POLB 145/4885ALDH1A1 1909/4885SMN1; SMN2 3181/4885 |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | MAPT, TTR, HTT | POLB 3454/4885ALDH1A1 2690/4885SMN1; SMN2 48/4885 |
| US-20100022617-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | ALPP, ALPG, DNTT | POLB 853/4885ALDH1A1 2278/4885SMN1; SMN2 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.